Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p

E. G. Seviour, V. Sehgal, D. Mishra, R. Rupaimoole, C. Rodriguez-Aguayo, G. Lopez-Berestein, J. S. Lee, A. K. Sood, M. P. Kim, Gordon Mills, P. T. Ram

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

KRas is mutated in a significant number of human cancers and so there is an urgent therapeutic need to target KRas signalling. To target KRas in lung cancers we used a systems approach of integrating a genome-wide miRNA screen with patient-derived phospho-proteomic signatures of the KRas downstream pathway, and identified miR-193a-3p, which directly targets KRas. Unique aspects of miR-193a-3p biology include two functionally independent target sites in the KRas 3′UTR and clinically significant correlation between miR-193a-3p and KRas expression in patients. Rescue experiments with mutated KRas 3'UTR showed very significantly that the anti-tumour effect of miR-193a-3p is via specific direct targeting of KRas and not due to other targets. Ex vivo and in vivo studies utilizing nanoliposome packaged miR-193a-3p demonstrated significant inhibition of tumour growth, circulating tumour cell viability and decreased metastasis. These studies show the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer.

Original languageEnglish (US)
Pages (from-to)1339-1350
Number of pages12
JournalOncogene
Volume36
Issue number10
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Neoplasm Metastasis
Growth
Neoplasms
3' Untranslated Regions
Systems Analysis
MicroRNAs
Proteomics
Lung Neoplasms
Cell Survival
Genome
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Seviour, E. G., Sehgal, V., Mishra, D., Rupaimoole, R., Rodriguez-Aguayo, C., Lopez-Berestein, G., ... Ram, P. T. (2017). Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p. Oncogene, 36(10), 1339-1350. https://doi.org/10.1038/onc.2016.308

Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p. / Seviour, E. G.; Sehgal, V.; Mishra, D.; Rupaimoole, R.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Lee, J. S.; Sood, A. K.; Kim, M. P.; Mills, Gordon; Ram, P. T.

In: Oncogene, Vol. 36, No. 10, 01.03.2017, p. 1339-1350.

Research output: Contribution to journalArticle

Seviour, EG, Sehgal, V, Mishra, D, Rupaimoole, R, Rodriguez-Aguayo, C, Lopez-Berestein, G, Lee, JS, Sood, AK, Kim, MP, Mills, G & Ram, PT 2017, 'Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p', Oncogene, vol. 36, no. 10, pp. 1339-1350. https://doi.org/10.1038/onc.2016.308
Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G et al. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p. Oncogene. 2017 Mar 1;36(10):1339-1350. https://doi.org/10.1038/onc.2016.308
Seviour, E. G. ; Sehgal, V. ; Mishra, D. ; Rupaimoole, R. ; Rodriguez-Aguayo, C. ; Lopez-Berestein, G. ; Lee, J. S. ; Sood, A. K. ; Kim, M. P. ; Mills, Gordon ; Ram, P. T. / Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p. In: Oncogene. 2017 ; Vol. 36, No. 10. pp. 1339-1350.
@article{163d17fba72b4d06a053cff31f562b47,
title = "Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p",
abstract = "KRas is mutated in a significant number of human cancers and so there is an urgent therapeutic need to target KRas signalling. To target KRas in lung cancers we used a systems approach of integrating a genome-wide miRNA screen with patient-derived phospho-proteomic signatures of the KRas downstream pathway, and identified miR-193a-3p, which directly targets KRas. Unique aspects of miR-193a-3p biology include two functionally independent target sites in the KRas 3′UTR and clinically significant correlation between miR-193a-3p and KRas expression in patients. Rescue experiments with mutated KRas 3'UTR showed very significantly that the anti-tumour effect of miR-193a-3p is via specific direct targeting of KRas and not due to other targets. Ex vivo and in vivo studies utilizing nanoliposome packaged miR-193a-3p demonstrated significant inhibition of tumour growth, circulating tumour cell viability and decreased metastasis. These studies show the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer.",
author = "Seviour, {E. G.} and V. Sehgal and D. Mishra and R. Rupaimoole and C. Rodriguez-Aguayo and G. Lopez-Berestein and Lee, {J. S.} and Sood, {A. K.} and Kim, {M. P.} and Gordon Mills and Ram, {P. T.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/onc.2016.308",
language = "English (US)",
volume = "36",
pages = "1339--1350",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant MIR-193a-3p

AU - Seviour, E. G.

AU - Sehgal, V.

AU - Mishra, D.

AU - Rupaimoole, R.

AU - Rodriguez-Aguayo, C.

AU - Lopez-Berestein, G.

AU - Lee, J. S.

AU - Sood, A. K.

AU - Kim, M. P.

AU - Mills, Gordon

AU - Ram, P. T.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - KRas is mutated in a significant number of human cancers and so there is an urgent therapeutic need to target KRas signalling. To target KRas in lung cancers we used a systems approach of integrating a genome-wide miRNA screen with patient-derived phospho-proteomic signatures of the KRas downstream pathway, and identified miR-193a-3p, which directly targets KRas. Unique aspects of miR-193a-3p biology include two functionally independent target sites in the KRas 3′UTR and clinically significant correlation between miR-193a-3p and KRas expression in patients. Rescue experiments with mutated KRas 3'UTR showed very significantly that the anti-tumour effect of miR-193a-3p is via specific direct targeting of KRas and not due to other targets. Ex vivo and in vivo studies utilizing nanoliposome packaged miR-193a-3p demonstrated significant inhibition of tumour growth, circulating tumour cell viability and decreased metastasis. These studies show the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer.

AB - KRas is mutated in a significant number of human cancers and so there is an urgent therapeutic need to target KRas signalling. To target KRas in lung cancers we used a systems approach of integrating a genome-wide miRNA screen with patient-derived phospho-proteomic signatures of the KRas downstream pathway, and identified miR-193a-3p, which directly targets KRas. Unique aspects of miR-193a-3p biology include two functionally independent target sites in the KRas 3′UTR and clinically significant correlation between miR-193a-3p and KRas expression in patients. Rescue experiments with mutated KRas 3'UTR showed very significantly that the anti-tumour effect of miR-193a-3p is via specific direct targeting of KRas and not due to other targets. Ex vivo and in vivo studies utilizing nanoliposome packaged miR-193a-3p demonstrated significant inhibition of tumour growth, circulating tumour cell viability and decreased metastasis. These studies show the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer.

UR - http://www.scopus.com/inward/record.url?scp=85027956111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027956111&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.308

DO - 10.1038/onc.2016.308

M3 - Article

VL - 36

SP - 1339

EP - 1350

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 10

ER -